newsfilter
← Latest News
Business Wire·

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

- Bomedemstat continues to be generally well-tolerated - - Bomedemstat demonstrated encouraging and distinct clinical benefit to patients with advanced myelofibrosis - - Data highlights rationale for bomedemstat as potential MF mono- or combinatio